Insulet (NASDAQ:PODD) Upgraded at Zacks Research

Zacks Research upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a strong-buy rating in a research note released on Tuesday,Zacks.com reports.

PODD has been the topic of several other reports. The Goldman Sachs Group lowered their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Truist Financial started coverage on shares of Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 target price on the stock. Oppenheimer increased their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Rothschild & Co Redburn increased their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Finally, Citigroup restated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $348.05.

Insulet Trading Up 1.2%

Insulet stock opened at $316.29 on Tuesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a market capitalization of $22.26 billion, a price-to-earnings ratio of 96.14, a PEG ratio of 2.61 and a beta of 1.40. Insulet has a one year low of $226.50 and a one year high of $353.50. The company’s fifty day moving average price is $325.99 and its two-hundred day moving average price is $301.60.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently made changes to their positions in the stock. Avanza Fonder AB lifted its stake in shares of Insulet by 23.8% in the third quarter. Avanza Fonder AB now owns 8,074 shares of the medical instruments supplier’s stock valued at $2,493,000 after buying an additional 1,552 shares during the period. CWM LLC lifted its stake in shares of Insulet by 7.8% in the third quarter. CWM LLC now owns 4,713 shares of the medical instruments supplier’s stock valued at $1,455,000 after buying an additional 343 shares during the period. Brookstone Capital Management lifted its stake in shares of Insulet by 191.2% in the third quarter. Brookstone Capital Management now owns 2,411 shares of the medical instruments supplier’s stock valued at $744,000 after buying an additional 1,583 shares during the period. Swedbank AB lifted its stake in shares of Insulet by 6.9% in the third quarter. Swedbank AB now owns 77,488 shares of the medical instruments supplier’s stock valued at $23,923,000 after buying an additional 5,000 shares during the period. Finally, Net Worth Advisory Group bought a new position in Insulet during the third quarter worth about $269,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.